Health Canada approves a second vaccine targeting the BA.4 and BA.5 subvariants

Health Canada approves second vaccine targeting BA.4 and BA subvariants .5

UPGRADE DAY

Health Canada has approved the updated version of the COVID-19 Comirnaty vaccine from Pfizer-BioNTech which targets the BA.4 and BA.5 subvariants of Omicron and whose use as a dose of booster is approved for people 12 years of age and older.

“Health Canada licensed this vaccine following a thorough and independent scientific review of the evidence, which demonstrated the safety and efficacy of this vaccine”, it was indicated in a press release on Friday.

According to the ministry, this new version of the Pfizer-BioNTech vaccine should present a similar safety profile to that of the original vaccine against COVID-19.

Recall that Moderna's bivalent vaccine has been available in Quebec since last month for protection against these same two variants.